IdentificationGeneric Name(1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oximeDrugBank Accession NumberDB08553Background(1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1h-pyrazol-4-yl)-2,3-dihydro-1h-inden-1-one oxime is a solid. This compound belongs to the phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group. It targets the protein serine/threonine-protein kinase B-raf.
TypeSmall MoleculeGroupsExperimentalStructure


3DDownload MOLSDF3D-SDFPDBSMILESInChI


 Similar StructuresStructure for (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime (DB08553)× CloseWeightAverage: 373.4509 Monoisotopic: 373.190260383 Chemical FormulaC22H23N5OSynonymsNot AvailablePharmacologyIndicationNot AvailableReduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, & validate predictive machine-learning models with structured datasets.See howContraindications & Blackbox WarningsAvoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Learn more  Avoid life-threatening adverse drug events & improve clinical decision support.Learn morePharmacodynamicsNot AvailableMechanism of actionTargetActionsOrganismUSerine/threonine-protein kinase B-rafNot AvailableHumansAbsorptionNot AvailableVolume of distributionNot AvailableProtein bindingNot AvailableMetabolismNot AvailableRoute of eliminationNot AvailableHalf-lifeNot AvailableClearanceNot AvailableAdverse EffectsImprove decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Learn more  Improve decision support & research outcomes with our structured adverse effects data.Learn moreToxicityNot AvailablePathwaysNot AvailablePharmacogenomic Effects/ADRs 


Not AvailableInteractionsDrug Interactions 


This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist. Not AvailableFood InteractionsNot AvailableCategoriesDrug CategoriesNot AvailableChemical TaxonomyProvided by ClassyfireDescriptionThis compound belongs to the class of organic compounds known as indanes. These are compounds containing an indane moiety, which consists of a cyclopentane fused to a benzene ring.KingdomOrganic compoundsSuper ClassBenzenoidsClassIndanesSub ClassNot AvailableDirect ParentIndanesAlternative ParentsPyridines and derivatives / Piperidines / Pyrazoles / Ketoximes / Heteroaromatic compounds / Dialkylamines / Azacyclic compounds / Organopnictogen compounds / Organic oxygen compounds / Hydrocarbon derivativesSubstituentsAmine / Aromatic heteropolycyclic compound / Azacycle / Azole / Heteroaromatic compound / Hydrocarbon derivative / Indane / Ketoxime / Organic nitrogen compound / Organic oxygen compoundMolecular FrameworkAromatic heteropolycyclic compoundsExternal DescriptorsNot AvailableAffected organismsNot AvailableChemical IdentifiersUNIINot AvailableCAS numberNot AvailableInChI KeyKWEFZSZCLBHIEQ-YYADALCUSA-NInChIInChI=1S/C22H23N5O/c28-26-21-4-2-16-13-17(1-3-19(16)21)20-14-27(18-7-11-24-12-8-18)25-22(20)15-5-9-23-10-6-15/h1,3,5-6,9-10,13-14,18,24,28H,2,4,7-8,11-12H2/b26-21+IUPAC NameN-[(1E)-5-[1-(piperidin-4-yl)-3-(pyridin-4-yl)-1H-pyrazol-4-yl]-2,3-dihydro-1H-inden-1-ylidene]hydroxylamineSMILESO\N=C1/CCC2=CC(=CC=C12)C1=CN(N=C1C1=CC=NC=C1)C1CCNCC1ReferencesGeneral ReferencesNot AvailableExternal LinksPubChem Compound11653652PubChem Substance99445024ChemSpider9828390BindingDB50006650ChEMBLCHEMBL526479ZINCZINC000039110119PDBe LigandSM5PDB Entries3d4q / 3omvClinical TrialsClinical Trials 


PhaseStatusPurposeConditionsCountPharmacoeconomicsManufacturersNot AvailablePackagersNot AvailableDosage FormsNot AvailablePricesNot AvailablePatentsNot AvailablePropertiesStateSolidExperimental PropertiesNot AvailablePredicted PropertiesPropertyValueSourceWater Solubility0.0387 mg/mLALOGPSlogP2.39ALOGPSlogP1.14ChemaxonlogS-4ALOGPSpKa (Strongest Acidic)7.42ChemaxonpKa (Strongest Basic)10.12ChemaxonPhysiological Charge1ChemaxonHydrogen Acceptor Count5ChemaxonHydrogen Donor Count2ChemaxonPolar Surface Area75.33 Å2ChemaxonRotatable Bond Count3ChemaxonRefractivity120.35 m3·mol-1ChemaxonPolarizability41.93 Å3ChemaxonNumber of Rings5ChemaxonBioavailability1ChemaxonRule of FiveYesChemaxonGhose FilterYesChemaxonVeber's RuleNoChemaxonMDDR-like RuleNoChemaxonPredicted ADMET FeaturesPropertyValueProbabilityHuman Intestinal Absorption+0.993Blood Brain Barrier+0.9283Caco-2 permeable-0.5819P-glycoprotein substrateSubstrate0.6194P-glycoprotein inhibitor INon-inhibitor0.6358P-glycoprotein inhibitor IIInhibitor0.6311Renal organic cation transporterInhibitor0.622CYP450 2C9 substrateNon-substrate0.7101CYP450 2D6 substrateNon-substrate0.7173CYP450 3A4 substrateNon-substrate0.5384CYP450 1A2 substrateInhibitor0.67CYP450 2C9 inhibitorNon-inhibitor0.6444CYP450 2D6 inhibitorNon-inhibitor0.755CYP450 2C19 inhibitorNon-inhibitor0.6576CYP450 3A4 inhibitorNon-inhibitor0.6395CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6793Ames testAMES toxic0.5606CarcinogenicityNon-carcinogens0.8004BiodegradationNot ready biodegradable0.9937Rat acute toxicity2.5303 LD50, mol/kg Not applicablehERG inhibition (predictor I)Weak inhibitor0.6295hERG inhibition (predictor II)Inhibitor0.7564  ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397) SpectraMass Spec (NIST)Not AvailableSpectraSpectrumSpectrum TypeSplash KeyPredicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot AvailableTargetsBuild, predict & validate machine-learning modelsUse our structured and evidence-based datasets to unlock newinsights and accelerate drug research.Learn more  Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.Learn more


 Details1. Serine/threonine-protein kinase B-rafKindProteinOrganismHumansPharmacological actionUnknownGeneral FunctionProtein serine/threonine kinase activitySpecific FunctionProtein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron. Phosphorylates MAP2K1, a...Gene NameBRAFUniprot IDP15056Uniprot NameSerine/threonine-protein kinase B-rafMolecular Weight84436.135 DaReferencesBerman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article] ×Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice. Learn more   Drug created at September 15, 2010 21:32 / Updated at June 12, 2020 16:52 